Alan J. Korman
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Vir Biotechnology (Switzerland)(CH)Bluebird Bio (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer(2012)12,531 cited
- → Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer(2012)7,941 cited
- → Nivolumab plus Ipilimumab in Advanced Melanoma(2013)4,207 cited
- → Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates(2010)2,913 cited
- → Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens(2014)1,964 cited
- → Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape(2011)1,624 cited